MedPath
Found 103 clinical trials|View Analysis
Sort by:

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2
Not yet recruiting
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
T Acute Lymphoblastic Leukemia
Interventions
Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Procedure: Bone Marrow Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Biological: Filgrastim
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT06738368
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Venetoclax and Decitabine in R/R T-ALL

Phase 2
Not yet recruiting
Conditions
T Lymphoblastic Leukemia/Lymphoma
Interventions
First Posted Date
2024-12-02
Last Posted Date
2024-12-16
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
28
Registration Number
NCT06712121
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Demethylating Agents Combined with Venetoclax for High-risk T-Cell Lymphoma/leukemia Post-Transplant Relapse Prevention

Phase 2
Recruiting
Conditions
T-cell Acute Lymphoblastic Leukemia
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Relapse
Interventions
First Posted Date
2024-11-13
Last Posted Date
2024-11-15
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
59
Registration Number
NCT06686108
Locations
🇨🇳

Shanghai General Hospital, Shanghai, China

Isatuximab in Adult Patients with Cytologic or Molecular Relapsed/refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Phase 2
Recruiting
Conditions
T-ALL
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-12-05
Lead Sponsor
Goethe University
Target Recruit Count
40
Registration Number
NCT06648889
Locations
🇩🇪

Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie, Berlin, Germany

🇩🇪

University Hospital Erlangen AöR, Department of Medicine 5, Erlangen, Germany

🇩🇪

Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology, Frankfurt am Main, Germany

and more 4 locations

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

Early Phase 1
Recruiting
Conditions
T-Acute Lymphoblastic Leukemia
Interventions
Biological: CD5 CAR T-cells
First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Zhejiang University
Target Recruit Count
30
Registration Number
NCT06633354
Locations
🇨🇳

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

Phase 2
Active, not recruiting
Conditions
Lymphoblastic Lymphoma, Adult
Lymphoblastic Leukemia, Acute T-cell
Interventions
Drug: BCL-2 inhibitors combined with the HyperCVAD regimen
Other: Propensity score matching historical data
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
206
Registration Number
NCT06598722
Locations
🇨🇳

Shanghai General Hospital, Shanghai, China

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Phase 2
Not yet recruiting
Conditions
T-cell Acute Lymphoblastic Leukemia
T-Cell Lymphoblastic Lymphoma
Interventions
First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT06561074
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Study WU-CART-007 in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Phase 2
Not yet recruiting
Conditions
T-cell Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Interventions
First Posted Date
2024-07-23
Last Posted Date
2024-11-20
Lead Sponsor
Wugen, Inc.
Target Recruit Count
125
Registration Number
NCT06514794

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Phase 3
Not yet recruiting
Conditions
T-lymphoblastic Leukemia
T-lymphoblastic Lymphoma
Interventions
First Posted Date
2024-05-30
Last Posted Date
2024-05-30
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
83
Registration Number
NCT06434467
Locations
🇨🇳

The first hospital of Lanzhou University, Lanzhou, Gansu, China

🇨🇳

Anhui Provincial Hospital, Hefei, Anhui, China

🇨🇳

Aerospace Medical Center, Beijing, Beijing, China

and more 27 locations

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

Phase 1
Recruiting
Conditions
T Cell Leukemia
T-cell Acute Lymphoblastic Leukemia
T-Cell Lymphoma of CNS
T Cell Lymphoma
T Cell Prolymphocytic Leukemia
T Cell Childhood ALL
Interventions
Biological: CD5/CD7 CAR-T
First Posted Date
2024-05-17
Last Posted Date
2024-11-12
Lead Sponsor
Essen Biotech
Target Recruit Count
60
Registration Number
NCT06420076
Locations
🇨🇳

District One Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath